Back to Search Start Over

Toward measuring effective treatment coverage: critical bottlenecks in quality- and user-adjusted coverage for major depressive disorder.

Authors :
Vigo, Daniel
Haro, Josep Maria
Hwang, Irving
Aguilar-Gaxiola, Sergio
Alonso, Jordi
Borges, Guilherme
Bruffaerts, Ronny
Caldas-de-Almeida, Jose Miguel
de Girolamo, Giovanni
Florescu, Silvia
Gureje, Oye
Karam, Elie
Karam, Georges
Kovess-Masfety, Viviane
Lee, Sing
Navarro-Mateu, Fernando
Ojagbemi, Akin
Posada-Villa, Jose
Sampson, Nancy A.
Scott, Kate
Source :
Psychological Medicine. Jul2022, Vol. 52 Issue 10, p1948-1958. 11p.
Publication Year :
2022

Abstract

Background: Major depressive disorder (MDD) is a leading cause of morbidity and mortality. Shortfalls in treatment quantity and quality are well-established, but the specific gaps in pharmacotherapy and psychotherapy are poorly understood. This paper analyzes the gap in treatment coverage for MDD and identifies critical bottlenecks. Methods: Seventeen surveys were conducted across 15 countries by the World Health Organization-World Mental Health Surveys Initiative. Of 35 012 respondents, 3341 met DSM-IV criteria for 12-month MDD. The following components of effective treatment coverage were analyzed: (a) any mental health service utilization; (b) adequate pharmacotherapy; (c) adequate psychotherapy; and (d) adequate severity-specific combination of both. Results: MDD prevalence was 4.8% (s.e., 0.2). A total of 41.8% (s.e., 1.1) received any mental health services, 23.2% (s.e., 1.5) of which was deemed effective. This 90% gap in effective treatment is due to lack of utilization (58%) and inadequate quality or adherence (32%). Critical bottlenecks are underutilization of psychotherapy (26 percentage-points reduction in coverage), underutilization of psychopharmacology (13-point reduction), inadequate physician monitoring (13-point reduction), and inadequate drug-type (10-point reduction). High-income countries double low-income countries in any mental health service utilization, adequate pharmacotherapy, adequate psychotherapy, and adequate combination of both. Severe cases are more likely than mild-moderate cases to receive either adequate pharmacotherapy or psychotherapy, but less likely to receive an adequate combination. Conclusions: Decision-makers need to increase the utilization and quality of pharmacotherapy and psychotherapy. Innovations such as telehealth for training and supervision plus non-specialist or community resources to deliver pharmacotherapy and psychotherapy could address these bottlenecks. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00332917
Volume :
52
Issue :
10
Database :
Academic Search Index
Journal :
Psychological Medicine
Publication Type :
Academic Journal
Accession number :
159190553
Full Text :
https://doi.org/10.1017/S0033291720003797